Stem definition | Drug id | CAS RN |
---|---|---|
beta-adrenoreceptor antagonists | 1887 | 118457-14-0 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.35 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 11 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 14 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 17, 2007 | FDA | FOREST LABS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Bradycardia | 179.12 | 11.34 | 199 | 27837 | 64227 | 50512861 |
Acute kidney injury | 171.52 | 11.34 | 385 | 27651 | 227673 | 50349415 |
Hyponatraemia | 126.33 | 11.34 | 206 | 27830 | 95933 | 50481155 |
Hypertensive crisis | 126.30 | 11.34 | 83 | 27953 | 13071 | 50564017 |
Hypotension | 86.75 | 11.34 | 307 | 27729 | 235162 | 50341926 |
Drug interaction | 82.94 | 11.34 | 271 | 27765 | 199350 | 50377738 |
Anaemia | 78.72 | 11.34 | 312 | 27724 | 252144 | 50324944 |
Systemic lupus erythematosus | 65.24 | 11.34 | 3 | 28033 | 140619 | 50436469 |
Joint swelling | 62.30 | 11.34 | 29 | 28007 | 245257 | 50331831 |
Acute motor-sensory axonal neuropathy | 57.89 | 11.34 | 16 | 28020 | 272 | 50576816 |
Fall | 56.87 | 11.34 | 348 | 27688 | 334584 | 50242504 |
Lip oedema | 53.89 | 11.34 | 29 | 28007 | 3164 | 50573924 |
Synovitis | 53.33 | 11.34 | 4 | 28032 | 123861 | 50453227 |
Treatment failure | 52.62 | 11.34 | 7 | 28029 | 137630 | 50439458 |
Syncope | 51.22 | 11.34 | 149 | 27887 | 102853 | 50474235 |
Traumatic coma | 50.86 | 11.34 | 11 | 28025 | 61 | 50577027 |
Pain | 49.92 | 11.34 | 160 | 27876 | 578743 | 49998345 |
Maternal exposure during pregnancy | 48.80 | 11.34 | 14 | 28022 | 159764 | 50417324 |
Rheumatoid arthritis | 45.47 | 11.34 | 28 | 28008 | 202522 | 50374566 |
Arthropathy | 44.39 | 11.34 | 16 | 28020 | 157890 | 50419198 |
Glossodynia | 43.88 | 11.34 | 6 | 28030 | 115563 | 50461525 |
Ischaemic stroke | 43.80 | 11.34 | 49 | 27987 | 15899 | 50561189 |
Drug ineffective | 43.22 | 11.34 | 272 | 27764 | 819061 | 49758027 |
Hyperkalaemia | 40.32 | 11.34 | 85 | 27951 | 48004 | 50529084 |
Cardiac failure | 39.73 | 11.34 | 112 | 27924 | 75928 | 50501160 |
Angina pectoris | 39.72 | 11.34 | 60 | 27976 | 26128 | 50550960 |
Product prescribing error | 39.11 | 11.34 | 53 | 27983 | 20908 | 50556180 |
Therapeutic product effect decreased | 37.87 | 11.34 | 14 | 28022 | 136036 | 50441052 |
Dyspnoea | 37.00 | 11.34 | 464 | 27572 | 547144 | 50029944 |
Atrial fibrillation | 35.94 | 11.34 | 131 | 27905 | 101614 | 50475474 |
Melaena | 35.81 | 11.34 | 58 | 27978 | 26806 | 50550282 |
General physical health deterioration | 35.75 | 11.34 | 165 | 27871 | 142269 | 50434819 |
Sopor | 35.18 | 11.34 | 49 | 27987 | 19830 | 50557258 |
Rhabdomyolysis | 35.08 | 11.34 | 71 | 27965 | 38956 | 50538132 |
Cerebellar ataxia | 33.53 | 11.34 | 14 | 28022 | 864 | 50576224 |
Infusion related reaction | 33.35 | 11.34 | 27 | 28009 | 169530 | 50407558 |
Vertigo | 32.81 | 11.34 | 82 | 27954 | 51750 | 50525338 |
Exposure during pregnancy | 32.77 | 11.34 | 13 | 28023 | 121002 | 50456086 |
Hepatocellular injury | 31.87 | 11.34 | 54 | 27982 | 25893 | 50551195 |
Contraindicated product administered | 30.20 | 11.34 | 23 | 28013 | 148935 | 50428153 |
Hypomagnesaemia | 29.52 | 11.34 | 49 | 27987 | 23107 | 50553981 |
Hypokalaemia | 29.15 | 11.34 | 111 | 27925 | 87881 | 50489207 |
Swelling | 27.48 | 11.34 | 43 | 27993 | 200829 | 50376259 |
Drug hypersensitivity | 27.09 | 11.34 | 62 | 27974 | 250948 | 50326140 |
Erythrosis | 25.95 | 11.34 | 6 | 28030 | 47 | 50577041 |
Systemic infection | 25.87 | 11.34 | 16 | 28020 | 2267 | 50574821 |
Miosis | 25.74 | 11.34 | 24 | 28012 | 6286 | 50570802 |
Primary hyperaldosteronism | 25.41 | 11.34 | 6 | 28030 | 52 | 50577036 |
Abdominal discomfort | 25.16 | 11.34 | 57 | 27979 | 231584 | 50345504 |
Tongue oedema | 24.74 | 11.34 | 19 | 28017 | 3820 | 50573268 |
Retroperitoneal haematoma | 23.73 | 11.34 | 16 | 28020 | 2627 | 50574461 |
Chronic pigmented purpura | 23.06 | 11.34 | 6 | 28030 | 80 | 50577008 |
Asthenia | 23.04 | 11.34 | 274 | 27762 | 318768 | 50258320 |
Arthralgia | 22.81 | 11.34 | 146 | 27890 | 438556 | 50138532 |
Resting tremor | 22.54 | 11.34 | 10 | 28026 | 716 | 50576372 |
Walking disability | 22.52 | 11.34 | 12 | 28024 | 1284 | 50575804 |
Renin decreased | 22.11 | 11.34 | 6 | 28030 | 95 | 50576993 |
Infection | 21.82 | 11.34 | 39 | 27997 | 172915 | 50404173 |
Arrhythmia | 21.58 | 11.34 | 53 | 27983 | 33079 | 50544009 |
Angioedema | 21.16 | 11.34 | 57 | 27979 | 37619 | 50539469 |
Drug intolerance | 20.62 | 11.34 | 58 | 27978 | 219046 | 50358042 |
Pericarditis | 20.42 | 11.34 | 9 | 28027 | 78680 | 50498408 |
Cholestasis | 20.25 | 11.34 | 44 | 27992 | 25357 | 50551731 |
Disorientation | 20.25 | 11.34 | 54 | 27982 | 35430 | 50541658 |
Arterial spasm | 19.70 | 11.34 | 5 | 28031 | 60 | 50577028 |
Haematoma muscle | 19.35 | 11.34 | 9 | 28027 | 719 | 50576369 |
Agranulocytosis | 19.28 | 11.34 | 39 | 27997 | 21382 | 50555706 |
Blood aldosterone increased | 19.06 | 11.34 | 6 | 28030 | 163 | 50576925 |
Peripheral ischaemia | 18.88 | 11.34 | 17 | 28019 | 4259 | 50572829 |
Sprue-like enteropathy | 18.84 | 11.34 | 8 | 28028 | 515 | 50576573 |
Cerebral haematoma | 18.76 | 11.34 | 15 | 28021 | 3196 | 50573892 |
Adenocarcinoma metastatic | 18.67 | 11.34 | 5 | 28031 | 75 | 50577013 |
Hypoosmolar state | 18.59 | 11.34 | 6 | 28030 | 177 | 50576911 |
Aeromonas infection | 18.55 | 11.34 | 5 | 28031 | 77 | 50577011 |
Oedema peripheral | 18.41 | 11.34 | 150 | 27886 | 157811 | 50419277 |
Presyncope | 18.25 | 11.34 | 41 | 27995 | 24157 | 50552931 |
Rash | 18.21 | 11.34 | 155 | 27881 | 437316 | 50139772 |
Discomfort | 18.09 | 11.34 | 20 | 28016 | 108360 | 50468728 |
Urine output increased | 18.06 | 11.34 | 10 | 28026 | 1154 | 50575934 |
Hemiparesis | 17.45 | 11.34 | 36 | 28000 | 20012 | 50557076 |
Blood loss anaemia | 17.38 | 11.34 | 22 | 28014 | 8117 | 50568971 |
Nocturia | 17.33 | 11.34 | 20 | 28016 | 6710 | 50570378 |
Drop attacks | 17.03 | 11.34 | 8 | 28028 | 654 | 50576434 |
Haematoma | 16.97 | 11.34 | 46 | 27990 | 30464 | 50546624 |
Product use issue | 16.86 | 11.34 | 36 | 28000 | 149439 | 50427649 |
Rectal haemorrhage | 16.54 | 11.34 | 53 | 27983 | 38505 | 50538583 |
Cerebral salt-wasting syndrome | 16.25 | 11.34 | 4 | 28032 | 42 | 50577046 |
Elephantiasis | 16.20 | 11.34 | 3 | 28033 | 6 | 50577082 |
Hypersensitivity pneumonitis | 16.09 | 11.34 | 12 | 28024 | 2310 | 50574778 |
Wound | 16.08 | 11.34 | 21 | 28015 | 105773 | 50471315 |
Dry gangrene | 16.04 | 11.34 | 7 | 28029 | 482 | 50576606 |
Hypoglycaemia | 15.65 | 11.34 | 65 | 27971 | 53516 | 50523572 |
Platelet disorder | 15.61 | 11.34 | 10 | 28026 | 1507 | 50575581 |
Metabolic acidosis | 15.43 | 11.34 | 52 | 27984 | 38773 | 50538315 |
Nasopharyngitis | 15.39 | 11.34 | 55 | 27981 | 192872 | 50384216 |
Diffuse large B-cell lymphoma stage II | 15.26 | 11.34 | 4 | 28032 | 55 | 50577033 |
Wrong schedule | 15.22 | 11.34 | 5 | 28031 | 156 | 50576932 |
Electrolyte imbalance | 15.15 | 11.34 | 31 | 28005 | 17138 | 50559950 |
Microcytic anaemia | 15.09 | 11.34 | 13 | 28023 | 3071 | 50574017 |
Orthostatic hypotension | 14.97 | 11.34 | 43 | 27993 | 29438 | 50547650 |
Hypersensitivity | 14.84 | 11.34 | 65 | 27971 | 215096 | 50361992 |
Anuria | 14.61 | 11.34 | 24 | 28012 | 11220 | 50565868 |
Musculoskeletal stiffness | 14.44 | 11.34 | 31 | 28005 | 128450 | 50448638 |
Nasal mucosal erosion | 14.36 | 11.34 | 4 | 28032 | 70 | 50577018 |
Vascular encephalopathy | 14.16 | 11.34 | 6 | 28030 | 384 | 50576704 |
Loss of personal independence in daily activities | 13.95 | 11.34 | 11 | 28025 | 70039 | 50507049 |
Renal function test abnormal | 13.92 | 11.34 | 12 | 28024 | 2837 | 50574251 |
Impaired healing | 13.85 | 11.34 | 11 | 28025 | 69775 | 50507313 |
Hyperammonaemia | 13.81 | 11.34 | 15 | 28021 | 4709 | 50572379 |
Intraventricular haemorrhage | 13.71 | 11.34 | 10 | 28026 | 1860 | 50575228 |
Sinus bradycardia | 13.07 | 11.34 | 25 | 28011 | 13158 | 50563930 |
Diaphragmatic disorder | 12.98 | 11.34 | 6 | 28030 | 473 | 50576615 |
Intra-abdominal haematoma | 12.97 | 11.34 | 9 | 28027 | 1548 | 50575540 |
Renal failure | 12.82 | 11.34 | 102 | 27934 | 106531 | 50470557 |
Product measured potency issue | 12.73 | 11.34 | 4 | 28032 | 108 | 50576980 |
Hypovolaemic shock | 12.66 | 11.34 | 15 | 28021 | 5173 | 50571915 |
Thrombocytopenia | 12.65 | 11.34 | 117 | 27919 | 127556 | 50449532 |
Cardiac failure acute | 12.65 | 11.34 | 19 | 28017 | 8231 | 50568857 |
Disease progression | 12.64 | 11.34 | 21 | 28015 | 95845 | 50481243 |
Haemorrhagic stroke | 12.57 | 11.34 | 15 | 28021 | 5213 | 50571875 |
Ductal adenocarcinoma of pancreas | 12.49 | 11.34 | 4 | 28032 | 115 | 50576973 |
Peripheral artery stenosis | 12.41 | 11.34 | 6 | 28030 | 523 | 50576565 |
Cerebral haemorrhage | 12.35 | 11.34 | 38 | 27998 | 27014 | 50550074 |
Prescription drug used without a prescription | 12.26 | 11.34 | 9 | 28027 | 1691 | 50575397 |
Blood pressure increased | 12.20 | 11.34 | 120 | 27916 | 133012 | 50444076 |
Gastrointestinal disorder | 12.17 | 11.34 | 21 | 28015 | 94435 | 50482653 |
Action tremor | 12.15 | 11.34 | 5 | 28031 | 297 | 50576791 |
Arterial thrombosis | 12.11 | 11.34 | 8 | 28028 | 1269 | 50575819 |
Mucosal hyperaemia | 12.06 | 11.34 | 3 | 28033 | 33 | 50577055 |
Withdrawal hypertension | 12.02 | 11.34 | 4 | 28032 | 130 | 50576958 |
Toxic skin eruption | 11.98 | 11.34 | 22 | 28014 | 11229 | 50565859 |
Psychotic behaviour | 11.95 | 11.34 | 6 | 28030 | 567 | 50576521 |
Labelled drug-drug interaction medication error | 11.81 | 11.34 | 21 | 28015 | 10456 | 50566632 |
Coronavirus infection | 11.68 | 11.34 | 11 | 28025 | 2918 | 50574170 |
Hypocalcaemia | 11.63 | 11.34 | 37 | 27999 | 26779 | 50550309 |
Haemodynamic instability | 11.62 | 11.34 | 18 | 28018 | 8006 | 50569082 |
International normalised ratio increased | 11.56 | 11.34 | 51 | 27985 | 43101 | 50533987 |
Diarrhoea | 11.56 | 11.34 | 416 | 27620 | 588060 | 49989028 |
Sinusitis | 11.47 | 11.34 | 52 | 27984 | 170506 | 50406582 |
Hypotonia | 11.44 | 11.34 | 18 | 28018 | 8116 | 50568972 |
Attention deficit hyperactivity disorder | 11.40 | 11.34 | 10 | 28026 | 2419 | 50574669 |
Disorganised speech | 11.37 | 11.34 | 7 | 28029 | 984 | 50576104 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute kidney injury | 132.50 | 11.60 | 473 | 22097 | 264794 | 29287163 |
Hyperkalaemia | 120.51 | 11.60 | 188 | 22382 | 61204 | 29490753 |
Lactic acidosis | 80.35 | 11.60 | 107 | 22463 | 30140 | 29521817 |
Bradycardia | 71.57 | 11.60 | 156 | 22414 | 65473 | 29486484 |
Hypoparathyroidism | 45.00 | 11.60 | 16 | 22554 | 458 | 29551499 |
Toxicity to various agents | 43.61 | 11.60 | 41 | 22529 | 173620 | 29378337 |
Syncope | 38.52 | 11.60 | 143 | 22427 | 81228 | 29470729 |
Hypokalaemia | 38.26 | 11.60 | 104 | 22466 | 50099 | 29501858 |
Hypotension | 38.00 | 11.60 | 266 | 22304 | 194088 | 29357869 |
Cerebral haematoma | 35.35 | 11.60 | 28 | 22542 | 4268 | 29547689 |
Hypertensive crisis | 34.58 | 11.60 | 36 | 22534 | 7812 | 29544145 |
Death | 32.91 | 11.60 | 142 | 22428 | 341942 | 29210015 |
Renal artery thrombosis | 32.01 | 11.60 | 11 | 22559 | 284 | 29551673 |
Burnout syndrome | 30.52 | 11.60 | 9 | 22561 | 139 | 29551818 |
Shock haemorrhagic | 30.42 | 11.60 | 37 | 22533 | 9514 | 29542443 |
Product monitoring error | 30.21 | 11.60 | 21 | 22549 | 2624 | 29549333 |
Ischaemic stroke | 28.64 | 11.60 | 47 | 22523 | 15930 | 29536027 |
Pemphigoid | 28.53 | 11.60 | 32 | 22538 | 7549 | 29544408 |
Anaemia | 28.25 | 11.60 | 255 | 22315 | 200696 | 29351261 |
Cerebellar ischaemia | 27.34 | 11.60 | 8 | 22562 | 120 | 29551837 |
Presyncope | 27.06 | 11.60 | 46 | 22524 | 16043 | 29535914 |
Blood lactic acid | 26.61 | 11.60 | 10 | 22560 | 336 | 29551621 |
Renal failure | 26.55 | 11.60 | 168 | 22402 | 118431 | 29433526 |
Cutaneous lupus erythematosus | 25.43 | 11.60 | 12 | 22558 | 716 | 29551241 |
Cerebellar syndrome | 25.40 | 11.60 | 17 | 22553 | 1997 | 29549960 |
Intercapillary glomerulosclerosis | 24.88 | 11.60 | 6 | 22564 | 40 | 29551917 |
Cardiac failure | 24.85 | 11.60 | 123 | 22447 | 79164 | 29472793 |
Coma uraemic | 24.76 | 11.60 | 6 | 22564 | 41 | 29551916 |
Fungal endocarditis | 24.60 | 11.60 | 9 | 22561 | 280 | 29551677 |
Febrile neutropenia | 24.25 | 11.60 | 30 | 22540 | 112210 | 29439747 |
Melaena | 24.16 | 11.60 | 65 | 22505 | 31111 | 29520846 |
Vitamin B12 decreased | 24.01 | 11.60 | 13 | 22557 | 1039 | 29550918 |
Brief psychotic disorder with marked stressors | 23.95 | 11.60 | 8 | 22562 | 189 | 29551768 |
Vascular purpura | 23.07 | 11.60 | 14 | 22556 | 1389 | 29550568 |
Laryngeal cancer metastatic | 22.82 | 11.60 | 6 | 22564 | 59 | 29551898 |
Vertigo | 22.70 | 11.60 | 51 | 22519 | 21810 | 29530147 |
Angina pectoris | 22.52 | 11.60 | 59 | 22511 | 27791 | 29524166 |
Decreased ventricular preload | 22.48 | 11.60 | 5 | 22565 | 22 | 29551935 |
Cholestasis | 22.45 | 11.60 | 53 | 22517 | 23409 | 29528548 |
Renal ischaemia | 22.36 | 11.60 | 10 | 22560 | 527 | 29551430 |
Cardiac failure chronic | 22.15 | 11.60 | 26 | 22544 | 6441 | 29545516 |
Labelled drug-drug interaction medication error | 22.10 | 11.60 | 36 | 22534 | 12123 | 29539834 |
Hepatocellular injury | 21.43 | 11.60 | 49 | 22521 | 21194 | 29530763 |
Bronchitis bacterial | 20.42 | 11.60 | 10 | 22560 | 648 | 29551309 |
White blood cell count decreased | 19.38 | 11.60 | 21 | 22549 | 83341 | 29468616 |
Enzyme induction | 19.13 | 11.60 | 5 | 22565 | 48 | 29551909 |
Potentiating drug interaction | 18.91 | 11.60 | 20 | 22550 | 4418 | 29547539 |
Platelet count decreased | 18.66 | 11.60 | 32 | 22538 | 104640 | 29447317 |
Agoraphobia | 18.63 | 11.60 | 7 | 22563 | 235 | 29551722 |
Infective exacerbation of chronic obstructive airways disease | 18.61 | 11.60 | 13 | 22557 | 1637 | 29550320 |
Left ventricle outflow tract obstruction | 18.40 | 11.60 | 6 | 22564 | 131 | 29551826 |
Neurosis | 17.95 | 11.60 | 6 | 22564 | 142 | 29551815 |
Hepatic function abnormal | 17.92 | 11.60 | 4 | 22566 | 39255 | 29512702 |
Acute coronary syndrome | 17.84 | 11.60 | 33 | 22537 | 12292 | 29539665 |
Carbohydrate metabolism disorder | 17.56 | 11.60 | 4 | 22566 | 20 | 29551937 |
Retinal disorder | 17.47 | 11.60 | 10 | 22560 | 890 | 29551067 |
Metabolic alkalosis | 16.97 | 11.60 | 11 | 22559 | 1225 | 29550732 |
Anticoagulation drug level increased | 16.82 | 11.60 | 8 | 22562 | 486 | 29551471 |
Dialysis device insertion | 16.68 | 11.60 | 4 | 22566 | 26 | 29551931 |
Haematoma | 16.60 | 11.60 | 47 | 22523 | 23165 | 29528792 |
Transient ischaemic attack | 16.52 | 11.60 | 47 | 22523 | 23223 | 29528734 |
Normocytic anaemia | 16.42 | 11.60 | 13 | 22557 | 1979 | 29549978 |
Electrocardiogram T wave abnormal | 16.07 | 11.60 | 11 | 22559 | 1340 | 29550617 |
Drug interaction | 16.04 | 11.60 | 225 | 22345 | 197160 | 29354797 |
Coma | 15.94 | 11.60 | 66 | 22504 | 39384 | 29512573 |
Blood creatine phosphokinase MB increased | 15.64 | 11.60 | 12 | 22558 | 1745 | 29550212 |
Neutrophil count decreased | 15.36 | 11.60 | 7 | 22563 | 43560 | 29508397 |
Hypomagnesaemia | 15.15 | 11.60 | 38 | 22532 | 17430 | 29534527 |
Perioral dermatitis | 15.01 | 11.60 | 5 | 22565 | 117 | 29551840 |
Disseminated aspergillosis | 14.89 | 11.60 | 7 | 22563 | 414 | 29551543 |
Diabetic nephropathy | 14.84 | 11.60 | 12 | 22558 | 1883 | 29550074 |
Haemorrhagic erosive gastritis | 14.78 | 11.60 | 5 | 22565 | 123 | 29551834 |
Hypertensive nephropathy | 14.72 | 11.60 | 7 | 22563 | 425 | 29551532 |
Drug abuse | 14.62 | 11.60 | 24 | 22546 | 79859 | 29472098 |
Atrial tachycardia | 14.59 | 11.60 | 12 | 22558 | 1929 | 29550028 |
Traumatic haemothorax | 14.59 | 11.60 | 6 | 22564 | 257 | 29551700 |
Brain natriuretic peptide increased | 14.48 | 11.60 | 17 | 22553 | 4213 | 29547744 |
Funguria | 13.93 | 11.60 | 4 | 22566 | 56 | 29551901 |
Dermatosis | 13.85 | 11.60 | 6 | 22564 | 293 | 29551664 |
Interstitial lung disease | 13.67 | 11.60 | 83 | 22487 | 57635 | 29494322 |
Extrasystoles | 13.65 | 11.60 | 15 | 22555 | 3459 | 29548498 |
Carcinogenicity | 13.61 | 11.60 | 4 | 22566 | 61 | 29551896 |
Congenital inguinal hernia | 13.59 | 11.60 | 5 | 22565 | 158 | 29551799 |
Palpitations | 13.53 | 11.60 | 55 | 22515 | 32549 | 29519408 |
Orthostatic hypotension | 13.51 | 11.60 | 43 | 22527 | 22586 | 29529371 |
Haemoglobinaemia | 13.51 | 11.60 | 5 | 22565 | 161 | 29551796 |
Electrocardiogram QT prolonged | 13.47 | 11.60 | 59 | 22511 | 36078 | 29515879 |
Oral lichen planus | 13.36 | 11.60 | 5 | 22565 | 166 | 29551791 |
Cardioactive drug level decreased | 13.15 | 11.60 | 4 | 22566 | 69 | 29551888 |
Anuria | 13.13 | 11.60 | 25 | 22545 | 9516 | 29542441 |
Epilepsy | 12.86 | 11.60 | 37 | 22533 | 18395 | 29533562 |
Gingival discomfort | 12.84 | 11.60 | 4 | 22566 | 75 | 29551882 |
Albumin urine present | 12.58 | 11.60 | 6 | 22564 | 367 | 29551590 |
Pain | 12.55 | 11.60 | 78 | 22492 | 171354 | 29380603 |
IIIrd nerve disorder | 12.24 | 11.60 | 4 | 22566 | 88 | 29551869 |
Acute pulmonary oedema | 12.22 | 11.60 | 20 | 22550 | 6759 | 29545198 |
Malpositioned teeth | 12.08 | 11.60 | 3 | 22567 | 23 | 29551934 |
Tachyarrhythmia | 11.98 | 11.60 | 13 | 22557 | 2956 | 29549001 |
Pancreatitis acute | 11.64 | 11.60 | 43 | 22527 | 24342 | 29527615 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Acute kidney injury | 300.69 | 10.71 | 824 | 43163 | 448416 | 64006329 |
Bradycardia | 202.41 | 10.71 | 320 | 43667 | 117899 | 64336846 |
Hyperkalaemia | 155.75 | 10.71 | 261 | 43726 | 100868 | 64353877 |
Hypertensive crisis | 153.28 | 10.71 | 115 | 43872 | 18133 | 64436612 |
Hypotension | 104.92 | 10.71 | 525 | 43462 | 380449 | 64074296 |
Anaemia | 103.69 | 10.71 | 521 | 43466 | 378159 | 64076586 |
Hyponatraemia | 101.52 | 10.71 | 275 | 43712 | 148064 | 64306681 |
Syncope | 84.60 | 10.71 | 268 | 43719 | 157367 | 64297378 |
Drug interaction | 82.61 | 10.71 | 474 | 43513 | 361609 | 64093136 |
Lactic acidosis | 78.33 | 10.71 | 146 | 43841 | 61264 | 64393481 |
Ischaemic stroke | 67.64 | 10.71 | 91 | 43896 | 28944 | 64425801 |
Melaena | 58.17 | 10.71 | 119 | 43868 | 53429 | 64401316 |
Vertigo | 56.99 | 10.71 | 125 | 43862 | 58886 | 64395859 |
Pain | 56.08 | 10.71 | 192 | 43795 | 553319 | 63901426 |
Fall | 55.64 | 10.71 | 479 | 43508 | 416347 | 64038398 |
Synovitis | 52.32 | 10.71 | 4 | 43983 | 99086 | 64355659 |
Cardiac failure | 51.92 | 10.71 | 203 | 43784 | 132170 | 64322575 |
Cerebral haematoma | 51.01 | 10.71 | 41 | 43946 | 7144 | 64447601 |
Hepatocellular injury | 50.88 | 10.71 | 102 | 43885 | 45133 | 64409612 |
Hypokalaemia | 49.48 | 10.71 | 189 | 43798 | 121714 | 64333031 |
Acute motor-sensory axonal neuropathy | 48.96 | 10.71 | 16 | 43971 | 396 | 64454349 |
Angina pectoris | 48.75 | 10.71 | 100 | 43887 | 44981 | 64409764 |
Joint swelling | 46.44 | 10.71 | 47 | 43940 | 215335 | 64239410 |
Traumatic coma | 45.03 | 10.71 | 10 | 43977 | 50 | 64454695 |
Cholestasis | 43.27 | 10.71 | 95 | 43892 | 44777 | 64409968 |
Presyncope | 42.96 | 10.71 | 82 | 43905 | 35007 | 64419738 |
Rheumatoid arthritis | 42.59 | 10.71 | 30 | 43957 | 164264 | 64290481 |
Toxicity to various agents | 41.76 | 10.71 | 119 | 43868 | 363394 | 64091351 |
General physical health deterioration | 40.38 | 10.71 | 258 | 43729 | 204167 | 64250578 |
Lip oedema | 39.82 | 10.71 | 31 | 43956 | 5158 | 64449587 |
Shock haemorrhagic | 39.68 | 10.71 | 53 | 43934 | 16738 | 64438007 |
Treatment failure | 39.67 | 10.71 | 15 | 43972 | 116801 | 64337944 |
Infusion related reaction | 38.86 | 10.71 | 33 | 43954 | 164434 | 64290311 |
Systemic lupus erythematosus | 38.63 | 10.71 | 4 | 43983 | 77608 | 64377137 |
Maternal exposure during pregnancy | 38.58 | 10.71 | 9 | 43978 | 95875 | 64358870 |
Drug hypersensitivity | 37.86 | 10.71 | 65 | 43922 | 237750 | 64216995 |
Therapeutic product effect decreased | 37.23 | 10.71 | 16 | 43971 | 115335 | 64339410 |
Exposure during pregnancy | 36.20 | 10.71 | 5 | 43982 | 77670 | 64377075 |
Hypomagnesaemia | 35.89 | 10.71 | 79 | 43908 | 37297 | 64417448 |
Arthropathy | 35.65 | 10.71 | 19 | 43968 | 120948 | 64333797 |
Haematoma | 32.85 | 10.71 | 87 | 43900 | 46163 | 64408582 |
Drug ineffective | 32.58 | 10.71 | 392 | 43595 | 839855 | 63614890 |
Dyspnoea | 32.53 | 10.71 | 678 | 43309 | 717996 | 63736749 |
Renal failure | 32.06 | 10.71 | 223 | 43764 | 181465 | 64273280 |
Labelled drug-drug interaction medication error | 31.36 | 10.71 | 55 | 43932 | 22007 | 64432738 |
Pemphigus | 30.54 | 10.71 | 3 | 43984 | 60698 | 64394047 |
Hepatic function abnormal | 30.30 | 10.71 | 4 | 43983 | 64309 | 64390436 |
Retro-orbital neoplasm | 29.52 | 10.71 | 7 | 43980 | 49 | 64454696 |
Anuria | 29.22 | 10.71 | 49 | 43938 | 18915 | 64435830 |
Arthralgia | 28.87 | 10.71 | 180 | 43807 | 442080 | 64012665 |
Renal artery thrombosis | 28.61 | 10.71 | 11 | 43976 | 442 | 64454303 |
Acute coronary syndrome | 28.57 | 10.71 | 49 | 43938 | 19261 | 64435484 |
Product monitoring error | 28.28 | 10.71 | 26 | 43961 | 5428 | 64449317 |
Atrial fibrillation | 26.74 | 10.71 | 204 | 43783 | 170885 | 64283860 |
Cerebellar ataxia | 26.45 | 10.71 | 16 | 43971 | 1767 | 64452978 |
Orthostatic hypotension | 26.45 | 10.71 | 81 | 43906 | 46657 | 64408088 |
Metabolic acidosis | 26.34 | 10.71 | 107 | 43880 | 70851 | 64383894 |
Agranulocytosis | 26.23 | 10.71 | 71 | 43916 | 38158 | 64416587 |
Pemphigoid | 26.21 | 10.71 | 38 | 43949 | 12948 | 64441797 |
Haemorrhagic stroke | 25.99 | 10.71 | 33 | 43954 | 9918 | 64444827 |
Vascular purpura | 25.77 | 10.71 | 18 | 43969 | 2538 | 64452207 |
Coma uraemic | 25.30 | 10.71 | 6 | 43981 | 42 | 64454703 |
Nasopharyngitis | 24.90 | 10.71 | 61 | 43926 | 196012 | 64258733 |
Asthenia | 24.89 | 10.71 | 420 | 43567 | 427624 | 64027121 |
Blood lactic acid | 24.87 | 10.71 | 10 | 43977 | 453 | 64454292 |
Hypoglycaemia | 24.70 | 10.71 | 124 | 43863 | 89768 | 64364977 |
Death | 24.06 | 10.71 | 212 | 43775 | 482493 | 63972252 |
Cardiac failure chronic | 23.64 | 10.71 | 30 | 43957 | 9011 | 64445734 |
White blood cell count decreased | 23.44 | 10.71 | 45 | 43942 | 157792 | 64296953 |
Sopor | 23.34 | 10.71 | 58 | 43929 | 29603 | 64425142 |
Intercapillary glomerulosclerosis | 23.22 | 10.71 | 6 | 43981 | 62 | 64454683 |
Product prescribing error | 22.70 | 10.71 | 64 | 43923 | 35205 | 64419540 |
Brief psychotic disorder with marked stressors | 22.33 | 10.71 | 8 | 43979 | 263 | 64454482 |
Infective exacerbation of chronic obstructive airways disease | 21.89 | 10.71 | 16 | 43971 | 2422 | 64452323 |
Retroperitoneal haematoma | 21.64 | 10.71 | 21 | 43966 | 4690 | 64450055 |
Carbohydrate metabolism disorder | 21.61 | 10.71 | 5 | 43982 | 31 | 64454714 |
Interstitial lung disease | 21.57 | 10.71 | 127 | 43860 | 97605 | 64357140 |
Blood loss anaemia | 21.54 | 10.71 | 36 | 43951 | 13856 | 64440889 |
Hypoparathyroidism | 21.51 | 10.71 | 11 | 43976 | 876 | 64453869 |
Cerebral haemorrhage | 21.36 | 10.71 | 80 | 43907 | 51010 | 64403735 |
Burnout syndrome | 21.33 | 10.71 | 8 | 43979 | 300 | 64454445 |
Decreased ventricular preload | 21.21 | 10.71 | 5 | 43982 | 34 | 64454711 |
Musculoskeletal stiffness | 21.16 | 10.71 | 32 | 43955 | 123174 | 64331571 |
Hyperlactacidaemia | 21.15 | 10.71 | 21 | 43966 | 4823 | 64449922 |
Walking disability | 20.95 | 10.71 | 14 | 43973 | 1837 | 64452908 |
Acute pulmonary oedema | 20.95 | 10.71 | 34 | 43953 | 12775 | 64441970 |
Glossodynia | 20.83 | 10.71 | 9 | 43978 | 64687 | 64390058 |
Erythrosis | 20.70 | 10.71 | 6 | 43981 | 98 | 64454647 |
Cutaneous lupus erythematosus | 20.53 | 10.71 | 16 | 43971 | 2666 | 64452079 |
Cerebellar syndrome | 20.53 | 10.71 | 21 | 43966 | 4995 | 64449750 |
Sinusitis | 20.47 | 10.71 | 43 | 43944 | 145885 | 64308860 |
Bronchitis bacterial | 20.44 | 10.71 | 12 | 43975 | 1255 | 64453490 |
Renin decreased | 20.05 | 10.71 | 6 | 43981 | 110 | 64454635 |
Platelet count decreased | 19.89 | 10.71 | 54 | 43933 | 167657 | 64287088 |
Pancreatitis acute | 19.52 | 10.71 | 69 | 43918 | 42786 | 64411959 |
Laryngeal cancer metastatic | 19.50 | 10.71 | 5 | 43982 | 50 | 64454695 |
Sinus bradycardia | 19.33 | 10.71 | 46 | 43941 | 22847 | 64431898 |
Primary hyperaldosteronism | 19.07 | 10.71 | 6 | 43981 | 131 | 64454614 |
Neutrophil count decreased | 18.83 | 10.71 | 15 | 43972 | 77181 | 64377564 |
Cerebellar ischaemia | 18.34 | 10.71 | 6 | 43981 | 149 | 64454596 |
Hypocalcaemia | 17.97 | 10.71 | 66 | 43921 | 41687 | 64413058 |
Loss of personal independence in daily activities | 17.77 | 10.71 | 14 | 43973 | 72440 | 64382305 |
Contraindicated product administered | 17.58 | 10.71 | 29 | 43958 | 107800 | 64346945 |
Arterial thrombosis | 17.53 | 10.71 | 14 | 43973 | 2416 | 64452329 |
Fungal endocarditis | 17.52 | 10.71 | 8 | 43979 | 496 | 64454249 |
Electrolyte imbalance | 17.43 | 10.71 | 47 | 43940 | 25196 | 64429549 |
Chronic pigmented purpura | 17.30 | 10.71 | 6 | 43981 | 179 | 64454566 |
Sprue-like enteropathy | 17.27 | 10.71 | 10 | 43977 | 1019 | 64453726 |
Jaundice | 17.09 | 10.71 | 72 | 43915 | 48440 | 64406305 |
Epistaxis | 17.03 | 10.71 | 120 | 43867 | 98011 | 64356734 |
Febrile neutropenia | 17.02 | 10.71 | 68 | 43919 | 187589 | 64267156 |
Renal ischaemia | 16.80 | 10.71 | 10 | 43977 | 1073 | 64453672 |
Angioedema | 16.78 | 10.71 | 85 | 43902 | 61736 | 64393009 |
Helicobacter infection | 16.67 | 10.71 | 3 | 43984 | 38359 | 64416386 |
Haematoma muscle | 16.63 | 10.71 | 12 | 43975 | 1781 | 64452964 |
Diabetic nephropathy | 16.45 | 10.71 | 14 | 43973 | 2640 | 64452105 |
Adenocarcinoma metastatic | 16.45 | 10.71 | 5 | 43982 | 97 | 64454648 |
Blood aldosterone increased | 16.34 | 10.71 | 6 | 43981 | 212 | 64454533 |
Urine output increased | 16.23 | 10.71 | 12 | 43975 | 1849 | 64452896 |
Contraindicated product prescribed | 16.11 | 10.71 | 10 | 43977 | 1157 | 64453588 |
Enzyme induction | 15.85 | 10.71 | 5 | 43982 | 110 | 64454635 |
Muscle mass | 15.77 | 10.71 | 7 | 43980 | 406 | 64454339 |
Drug reaction with eosinophilia and systemic symptoms | 15.75 | 10.71 | 76 | 43911 | 54141 | 64400604 |
Pericarditis | 15.43 | 10.71 | 12 | 43975 | 62504 | 64392241 |
Abdominal discomfort | 15.34 | 10.71 | 68 | 43919 | 182254 | 64272491 |
Haemoglobinaemia | 15.29 | 10.71 | 6 | 43981 | 255 | 64454490 |
Intracranial mass | 15.23 | 10.71 | 12 | 43975 | 2031 | 64452714 |
Hypoosmolar state | 15.22 | 10.71 | 6 | 43981 | 258 | 64454487 |
Fibromyalgia | 15.09 | 10.71 | 3 | 43984 | 35728 | 64419017 |
Infection | 14.93 | 10.71 | 70 | 43917 | 184810 | 64269935 |
Palpitations | 14.89 | 10.71 | 122 | 43865 | 104366 | 64350379 |
Hepatic mass | 14.82 | 10.71 | 12 | 43975 | 2112 | 64452633 |
Elephantiasis | 14.72 | 10.71 | 3 | 43984 | 9 | 64454736 |
Hypotonia | 14.71 | 10.71 | 27 | 43960 | 11185 | 64443560 |
Poisoning deliberate | 14.71 | 10.71 | 30 | 43957 | 13428 | 64441317 |
Atrioventricular block | 14.61 | 10.71 | 28 | 43959 | 11987 | 64442758 |
Dermatosis | 14.42 | 10.71 | 7 | 43980 | 499 | 64454246 |
Disease progression | 14.38 | 10.71 | 49 | 43938 | 141631 | 64313114 |
Resting tremor | 14.35 | 10.71 | 10 | 43977 | 1404 | 64453341 |
Vitamin B12 decreased | 14.19 | 10.71 | 13 | 43974 | 2702 | 64452043 |
Language disorder | 14.18 | 10.71 | 13 | 43974 | 2704 | 64452041 |
Dialysis device insertion | 14.18 | 10.71 | 4 | 43983 | 59 | 64454686 |
Arterial spasm | 14.17 | 10.71 | 5 | 43982 | 157 | 64454588 |
Mobility decreased | 14.07 | 10.71 | 23 | 43964 | 85817 | 64368928 |
Systemic infection | 14.02 | 10.71 | 16 | 43971 | 4305 | 64450440 |
Oedema peripheral | 13.93 | 10.71 | 211 | 43776 | 210106 | 64244639 |
Coronavirus infection | 13.91 | 10.71 | 18 | 43969 | 5512 | 64449233 |
Renal impairment | 13.88 | 10.71 | 147 | 43840 | 134870 | 64319875 |
Body temperature increased | 13.68 | 10.71 | 4 | 43983 | 36662 | 64418083 |
Drug dependence | 13.65 | 10.71 | 3 | 43984 | 33309 | 64421436 |
Nasal mucosal erosion | 13.54 | 10.71 | 4 | 43983 | 70 | 64454675 |
Brain natriuretic peptide increased | 13.50 | 10.71 | 21 | 43966 | 7612 | 64447133 |
Renal function test abnormal | 13.38 | 10.71 | 15 | 43972 | 3959 | 64450786 |
Erysipelas | 13.37 | 10.71 | 23 | 43964 | 9058 | 64445687 |
Sinus rhythm | 13.36 | 10.71 | 7 | 43980 | 586 | 64454159 |
Dermatitis bullous | 13.33 | 10.71 | 27 | 43960 | 12027 | 64442718 |
Back pain | 13.27 | 10.71 | 108 | 43879 | 250063 | 64204682 |
Product use issue | 13.11 | 10.71 | 56 | 43931 | 151659 | 64303086 |
Product measured potency issue | 13.07 | 10.71 | 5 | 43982 | 198 | 64454547 |
Carcinogenicity | 12.90 | 10.71 | 4 | 43983 | 83 | 64454662 |
Traumatic haemothorax | 12.82 | 10.71 | 6 | 43981 | 394 | 64454351 |
Tongue oedema | 12.78 | 10.71 | 18 | 43969 | 5972 | 64448773 |
Hypersensitivity | 12.76 | 10.71 | 80 | 43907 | 196372 | 64258373 |
Extrasystoles | 12.74 | 10.71 | 19 | 43968 | 6639 | 64448106 |
Blood creatinine increased | 12.66 | 10.71 | 145 | 43842 | 135637 | 64319108 |
Blood creatine phosphokinase MB increased | 12.64 | 10.71 | 12 | 43975 | 2609 | 64452136 |
Disseminated aspergillosis | 12.58 | 10.71 | 7 | 43980 | 661 | 64454084 |
Rhabdomyolysis | 12.48 | 10.71 | 106 | 43881 | 91620 | 64363125 |
Anticoagulation drug level increased | 12.47 | 10.71 | 7 | 43980 | 672 | 64454073 |
Stomatitis | 12.46 | 10.71 | 36 | 43951 | 109569 | 64345176 |
Arrhythmia | 12.46 | 10.71 | 70 | 43917 | 52874 | 64401871 |
Polyuria | 12.45 | 10.71 | 27 | 43960 | 12616 | 64442129 |
Diffuse large B-cell lymphoma stage II | 12.39 | 10.71 | 4 | 43983 | 95 | 64454650 |
Electrocardiogram abnormal | 12.38 | 10.71 | 28 | 43959 | 13453 | 64441292 |
Loss of consciousness | 12.32 | 10.71 | 155 | 43832 | 148210 | 64306535 |
Drop attacks | 12.27 | 10.71 | 8 | 43979 | 1007 | 64453738 |
Rash | 12.14 | 10.71 | 230 | 43757 | 458319 | 63996426 |
IIIrd nerve disorder | 12.13 | 10.71 | 4 | 43983 | 102 | 64454643 |
Malaise | 11.90 | 10.71 | 354 | 43633 | 395893 | 64058852 |
Bundle branch block left | 11.73 | 10.71 | 23 | 43964 | 10011 | 64444734 |
Potentiating drug interaction | 11.71 | 10.71 | 20 | 43967 | 7832 | 64446913 |
Cerebral salt-wasting syndrome | 11.71 | 10.71 | 4 | 43983 | 114 | 64454631 |
Perioral dermatitis | 11.64 | 10.71 | 5 | 43982 | 268 | 64454477 |
Alanine aminotransferase increased | 11.60 | 10.71 | 52 | 43935 | 138979 | 64315766 |
Lower respiratory tract infection | 11.56 | 10.71 | 30 | 43957 | 94584 | 64360161 |
Rectal haemorrhage | 11.56 | 10.71 | 77 | 43910 | 61740 | 64393005 |
Mitral valve incompetence | 11.53 | 10.71 | 41 | 43946 | 25497 | 64429248 |
Eosinophilia | 11.51 | 10.71 | 54 | 43933 | 38022 | 64416723 |
Microcytic anaemia | 11.51 | 10.71 | 15 | 43972 | 4623 | 64450122 |
Sedation | 11.51 | 10.71 | 7 | 43980 | 41455 | 64413290 |
Toxic skin eruption | 11.45 | 10.71 | 34 | 43953 | 19250 | 64435495 |
Thrombocytopenia | 11.34 | 10.71 | 215 | 43772 | 223586 | 64231159 |
Tonic clonic movements | 11.33 | 10.71 | 10 | 43977 | 1979 | 64452766 |
Intra-abdominal haematoma | 11.29 | 10.71 | 11 | 43976 | 2468 | 64452277 |
Atrial tachycardia | 11.25 | 10.71 | 13 | 43974 | 3546 | 64451199 |
Diarrhoea | 11.21 | 10.71 | 601 | 43386 | 722103 | 63732642 |
Dry gangrene | 11.19 | 10.71 | 7 | 43980 | 821 | 64453924 |
Lymphocyte count decreased | 11.12 | 10.71 | 7 | 43980 | 40692 | 64414053 |
Hypertensive nephropathy | 11.09 | 10.71 | 7 | 43980 | 834 | 64453911 |
Swelling | 11.06 | 10.71 | 64 | 43923 | 160154 | 64294591 |
Malpositioned teeth | 11.06 | 10.71 | 3 | 43984 | 38 | 64454707 |
Agoraphobia | 11.04 | 10.71 | 6 | 43981 | 541 | 64454204 |
Osteonecrosis of jaw | 10.98 | 10.71 | 55 | 43932 | 39770 | 64414975 |
Left ventricle outflow tract obstruction | 10.89 | 10.71 | 5 | 43982 | 314 | 64454431 |
Urinary retention | 10.89 | 10.71 | 64 | 43923 | 49137 | 64405608 |
Wrong schedule | 10.85 | 10.71 | 5 | 43982 | 317 | 64454428 |
Vascular encephalopathy | 10.79 | 10.71 | 6 | 43981 | 566 | 64454179 |
Condition aggravated | 10.73 | 10.71 | 184 | 43803 | 372242 | 64082503 |
None
Source | Code | Description |
---|---|---|
ATC | C07AB12 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, selective |
ATC | C07BB12 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Beta blocking agents, selective, and thiazides |
ATC | C07FB12 | CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS, OTHER COMBINATIONS Beta blocking agents and calcium channel blockers |
ATC | C09DX05 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations |
FDA MoA | N0000000161 | Adrenergic beta-Antagonists |
FDA EPC | N0000175556 | beta-Adrenergic Blocker |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D000322 | Adrenergic Agonists |
MeSH PA | D058665 | Adrenergic beta-1 Receptor Agonists |
MeSH PA | D000318 | Adrenergic beta-Agonists |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014665 | Vasodilator Agents |
CHEBI has role | CHEBI:35530 | beta-adrenergic blockers |
CHEBI has role | CHEBI:35620 | vasodilator agents |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:176497 | geroprotectors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypertensive disorder | indication | 38341003 | DOID:10763 |
Chronic heart failure | off-label use | 48447003 | |
Atrial fibrillation | off-label use | 49436004 | DOID:0060224 |
Angina pectoris | off-label use | 194828000 | |
Myocardial Reinfarction Prevention | off-label use | ||
Bronchospasm | contraindication | 4386001 | |
Complete atrioventricular block | contraindication | 27885002 | |
Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
Bradycardia | contraindication | 48867003 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Cardiogenic shock | contraindication | 89138009 | |
Second degree atrioventricular block | contraindication | 195042002 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypoglycemic disorder | contraindication | 237630007 | |
Peripheral vascular disease | contraindication | 400047006 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.87 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 5MG BASE;80MG | BYVALSON | ALLERGAN | N206302 | June 3, 2016 | DISCN | TABLET | ORAL | 7838552 | Oct. 4, 2027 | METHOD OF TREATING HYPERTENSION |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | ANTAGONIST | Ki | 8.50 | WOMBAT-PK | CHEMBL | |||
Beta-2 adrenergic receptor | GPCR | ANTAGONIST | Ki | 7.50 | WOMBAT-PK | CHEMBL | |||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 8 | WOMBAT-PK | |||||
Beta-3 adrenergic receptor | GPCR | ANTAGONIST | Ki | 5.66 | IUPHAR |
ID | Source |
---|---|
4027169 | VUID |
N0000179202 | NUI |
D05127 | KEGG_DRUG |
152520-56-4 | SECONDARY_CAS_RN |
4027169 | VANDF |
C0068475 | UMLSCUI |
CHEBI:64022 | CHEBI |
CHEMBL434394 | ChEMBL_ID |
CHEMBL1201731 | ChEMBL_ID |
D000068577 | MESH_DESCRIPTOR_UI |
DB04861 | DRUGBANK_ID |
71301 | PUBCHEM_CID |
7246 | IUPHAR_LIGAND_ID |
5969 | INN_ID |
030Y90569U | UNII |
236883 | RXNORM |
130026 | MMSL |
18486 | MMSL |
29969 | MMSL |
52690 | MMSL |
d05265 | MMSL |
007077 | NDDF |
007078 | NDDF |
318638009 | SNOMEDCT_US |
395808005 | SNOMEDCT_US |
734565001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Bystolic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-1402 | TABLET | 2.50 mg | ORAL | NDA | 26 sections |
Bystolic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-1402 | TABLET | 2.50 mg | ORAL | NDA | 26 sections |
Bystolic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-1405 | TABLET | 5 mg | ORAL | NDA | 26 sections |
Bystolic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-1405 | TABLET | 5 mg | ORAL | NDA | 26 sections |
Bystolic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-1410 | TABLET | 10 mg | ORAL | NDA | 26 sections |
Bystolic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-1410 | TABLET | 10 mg | ORAL | NDA | 26 sections |
Bystolic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-1420 | TABLET | 20 mg | ORAL | NDA | 26 sections |
Bystolic | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0456-1420 | TABLET | 20 mg | ORAL | NDA | 26 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7189 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7190 | TABLET | 10 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7225 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7226 | TABLET | 20 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-353 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-353 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-354 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-354 | TABLET | 5 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-355 | TABLET | 10 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-355 | TABLET | 10 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-356 | TABLET | 20 mg | ORAL | ANDA | 24 sections |
nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-356 | TABLET | 20 mg | ORAL | ANDA | 24 sections |
Nebivolol | Human Prescription Drug Label | 1 | 27241-179 | TABLET | 2.50 mg | ORAL | ANDA | 25 sections |
Nebivolol | Human Prescription Drug Label | 1 | 27241-180 | TABLET | 5 mg | ORAL | ANDA | 25 sections |
Nebivolol | Human Prescription Drug Label | 1 | 27241-181 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
Nebivolol | Human Prescription Drug Label | 1 | 27241-182 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
Nebivolol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-375 | TABLET | 2.50 mg | ORAL | ANDA | 23 sections |
Nebivolol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-376 | TABLET | 5 mg | ORAL | ANDA | 23 sections |
Nebivolol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-377 | TABLET | 10 mg | ORAL | ANDA | 23 sections |
Nebivolol Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 29300-378 | TABLET | 20 mg | ORAL | ANDA | 23 sections |
Nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-585 | TABLET | 2.50 mg | ORAL | ANDA | 24 sections |
Nebivolol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-586 | TABLET | 5 mg | ORAL | ANDA | 24 sections |